First reported by Fierce Biotech
AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
New experimental Alzheimer’s drug shows potential after study shows slower cognitive decline
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers found.
Read the full articleYou might also wanna read
STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage
STAT·2d ago
Biogen’s Alzheimer’s drug lowers toxic protein, but results were mixed
By Julie Steenhuysen CHICAGO, July 14 (Reuters) - The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary
y94.com·2d ago
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
San Bernardino Sun·2d ago
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
Broomfield Enterprise·2d ago
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
mainlinemedianews.com·2d ago
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
Sun Sentinel·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.